Abstract
Rationale The gut-lung axis describes the crosstalk between the gut and lung wherein microbiota in the gut modulate systemic anti-inflammatory and immune responses in the lungs. Objectives: We hypothesized that a blend of probiotic bacteria (Lactobacilli) combined with herbal extracts (resB®) could improve quality of life in COPD patients.
Methods We conducted a randomized, double-blinded, placebo-controlled study (NCT05523180) evaluating the safety and impact of resB® on quality of life in volunteers with COPD. Participants took two capsules of resB® or placebo orally daily for 12 weeks. The primary endpoint was quality of life changes by Saint George’s Respiratory Questionnaire (SGRQ). In addition to safety, exploratory endpoints included changes in serum and sputum biomarkers as well as sputum and stool microbiome.
Measurements and Main Results resB® was well tolerated by all participants, with no related adverse events reported. Participants who received resB® had improvement in their SGRQ symptom scores from baseline to final visit (P<0.05), while the change in SGRQ symptom scores in those receiving placebo was not significant. Serum and sputum concentrations of matrix metalloproteinase 9, serum c-reactive protein, and serum interleukin 6 decreased (P<0.05) between baseline and final visit in the resB® group, corresponding with an increase in stool Lactobacilli abundance. Relative abundance of Veillonella also increased in stool and sputum in the resB® group.
Conclusions Participants with COPD who received resB® improved in respiratory symptoms over a 12-week course. Serum and sputum biomarkers suggest administration of the probiotic and herbal blend reduces inflammation and may thereby attenuate symptoms.
Competing Interest Statement
ResBiotic Nutrition Inc. is a university startup out of the University of Alabama at Birmingham of which CL is the Founder, AG is the Chief Medical Officer, and NA is an Advisor. The authors declare that the research was conducted by a third-party contract research organization, in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Clinical Trial
NCT05523180
Funding Statement
Research reported in this publication was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under awards number K08 HL141652 (CL) and R44HL164156 (TN) and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UM1TR004771. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Sterling Institutional Review Board (Atlanta, Georgia, USA) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Contact Information: Charitharth Vivek Lal, MD1, Suite 9380, Women and Infants Center, University of Alabama at Birmingham, 1700 6th Ave South, Birmingham, AL 35233, Tel 205-934-4680, Fax 205-934-3100, Email: clal{at}uabmc.edu
Funding Research reported in this publication was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under awards number K08 HL141652 (CL) and R44HL164156 (TN) and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UM1TR004771. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
